Commercial Co-Founder: The Biotech Growth Advantage

Most biotech startups don’t fail because the science is bad. They fail because the company never becomes the obvious choice for a paying market.

That’s why I agree with a point Chervee Ho (CEO & Co-founder of BioChromatographix International) makes from lived experience: a biotech founder needs a commercial co-founder early—someone who wakes up thinking about customers, positioning, pricing, and the fastest credible route to adoption.

If you’re reading this as part of our Singapore Startup Marketing series, here’s the bigger idea: the “commercial co-founder” role in biotech is basically the startup equivalent of a strong, strategic growth function. And for Singapore SMEs trying to generate consistent leads, it’s the same lesson—great execution without market strategy is just expensive activity.

What a commercial co-founder really does (beyond “sales”)

A commercial co-founder’s job is simple to describe and hard to do: turn technical progress into market progress.

In biotech, “commercial” isn’t a logo, a pitch deck, or a few investor coffees. It’s a discipline that connects four moving parts:

• Market clarity: Who has the problem, how painful is it, and what are they using today?
• Positioning: Why you vs. the status quo, stated in a way a buyer can defend internally.
• Go-to-market sequencing: Which segment adopts first, and what proof do they need before switching?
• Revenue mechanics: Pricing, packaging, pilots, and procurement paths that don’t stall for months.

Chervee’s example at BCI is a clean illustration: the company’s AXISFLOW™ chromatography media may be technically strong, but technical strength doesn’t automatically create switching behaviour. A commercial lens forces a team to answer the daily question that matters: “Who needs this, and why now?”

Why “technology push” kills early-stage biotech

Many scientific founders build what they can build, not what customers will adopt.

A commercial co-founder prevents “technology push” by:

1. Running customer discovery before the product is “perfect”
2. Converting feedback into product priorities (not random feature requests)
3. Setting milestone language investors and partners actually recognise

A useful one-liner I use with founders is:

If you can’t explain the switching trigger in one sentence, you’re not ready to scale.

The biotech adoption problem is a marketing problem in disguise

Biotech commercialisation is often described as regulatory, technical, and capital-intensive (true). But on the ground, adoption still behaves like a market decision:

• Buyers default to what’s already validated.
• Procurement teams hate risk.
• Internal champions need evidence and a story they can repeat.

This is exactly why a commercial co-founder matters. They translate innovation into reduced perceived risk.

The buyer’s real question: “Can I defend this decision?”

In B2B biotech—whether you sell tools, platforms, materials, diagnostics, or enabling tech—your first customers aren’t just buying performance. They’re buying:

• Confidence (validation data, credible references)
• Operational fit (workflow compatibility, training needs)
• Economic logic (cost savings, yield improvement, throughput gains)

A commercial leader builds the package around those needs, not around scientific pride.

Finding the right commercial co-founder: a practical checklist

“Find a co-founder” is generic advice. What founders need is a hiring spec for a partner.

Here’s a more useful way to think about it—especially in Singapore’s startup ecosystem where talent is strong but time is limited.

1) Look for pattern recognition, not an impressive title

An MBA doesn’t equal commercial strength. Some of the best commercial operators in biotech come from:

• technical sales (they’ve seen real objections)
• regulatory and quality (they understand buyer risk)
• BD in pharma/bioprocessing (they know how deals really close)
• product marketing in deep tech (they can message complex value)

The test is straightforward: Can they make a complex product feel simple and urgent?

2) Validate “co-founder fit” with a paid sprint

Before you offer equity, run a 2–4 week sprint with clear outputs:

• 15–25 customer interviews completed
• one positioning statement and one ICP (ideal customer profile)
• a pilot offer (what’s included, timeline, success criteria)
• a pricing hypothesis (even if it’s wrong)

This reveals how they think under ambiguity—more than any coffee chat.

3) Ask a question that exposes judgement

One of my favourites:

• “What would you not build in the next 6 months, even if the science team wants it?”

Strong commercial co-founders have the courage to say no—and explain why.

4) Get explicit about values and operating style

Biotech timelines are long. When pressure hits, misalignment becomes expensive.

Discuss early:

• decision-making (consensus vs. strong owner)
• risk tolerance (how aggressive on pilots, claims, and timelines)
• communication cadence (weekly metrics, monthly strategy)
• what “good” looks like this quarter

Chervee’s story about complementary strengths is the point: great co-founders aren’t similar—they’re mutually trusted.

If you can’t find a commercial co-founder: what to do instead

Not everyone finds the perfect counterpart at the start. If that’s your reality, you can still build commercial muscle—just do it intentionally.

Build a “commercial spine” with three components

1. Advisory circle (2–3 people)

   • One pricing/market entry person
   • One domain buyer (someone who has signed the PO)
   • One operator who’s launched similar products

2. Fractional leadership

   • A fractional CCO or growth lead can set strategy and run discovery.

3. Founder-led selling (non-negotiable)

   • Even if you’re lab-first, you need direct exposure to objections and buying language.

A practical signal checklist (more predictive than patents or press):

• inbound requests for pilots or demos
• customers volunteering pain points without you prompting
• willingness to co-develop validation protocols
• procurement conversations starting earlier than expected

What Singapore SMEs can learn from biotech co-founder dynamics

Here’s the bridge back to the Singapore SME Digital Marketing campaign angle: many SMEs treat marketing like “extra execution” instead of a strategic role.

Biotech founders have a built-in excuse—regulatory complexity, long validation cycles, deep tech. SMEs don’t.

Yet the failure mode is similar:

• Lots of activity (posts, ads, occasional campaigns)
• Weak positioning (“we do everything”)
• No clear ICP (everyone is a customer)
• No conversion path (traffic doesn’t become leads)

A commercial co-founder solves this in a startup by owning the commercial system. For an SME, the equivalent is having a clear growth owner—an internal leader or a competent partner—who can connect:

• messaging → targeting → offer → lead capture → follow-up

The “commercial co-founder” mindset, translated to digital marketing

If you want more qualified leads in Singapore, apply these same principles:

• Answer “who needs this, and why now?” in your homepage hero and ad copy.
• Pick one primary audience (industry + role + pain) before you scale spend.
• Offer a low-friction first step (audit, consultation, sample, calculator, trial).
• Build proof like case studies, specific outcomes, and real constraints.

The stance I’ll take: If your marketing can’t produce a measurable pipeline within 90 days, it’s not “brand building”—it’s misalignment.

A simple operating model: align science milestones with market milestones

One of the strongest ideas in Chervee Ho’s article is that commercial leadership keeps teams grounded in what must be proven.

To make that actionable, here’s a dual-track milestone model you can use in biotech (and borrow for startups/SMEs too):

Science / product milestones

• Prototype ready
• Performance benchmarks hit
• Validation data captured
• QA/regulatory pathway clarified

Market milestones (equally important)

• ICP confirmed (documented)
• Switching triggers identified
• Pilot offer shipped
• First 3 referenceable users secured
• Pricing model tested with real buyers

When both tracks move together, companies gain momentum. When only the science moves, teams feel busy but the business stays fragile.

The real advantage: speed to learning (not speed to perfection)

Commercial co-founders don’t “rush” biotech. They compress learning cycles.

They’re the ones who:

• stop the team from building in a vacuum
• translate buyer objections into product requirements
• create narratives customers and investors repeat accurately
• push for pilots that generate proof, not just “interest”

And in a market like Singapore—where ecosystems, accelerators, and regional opportunities are strong—speed to learning is a competitive advantage you can actually control.

Most companies get this wrong: they try to market after they build.

There’s a better way to approach this: build commercial thinking into the founding team—or simulate it with advisors and fractional leadership—so the product and the market mature together.

Where does your company need a “commercial co-founder” mindset right now: positioning, pricing, pipeline, or conversion?